ioGlutamatergic Neurons TDP-43 M337V heterozygous - Human iPSC derived cells

Description

Wild type ioGlutamatergic Neurons ab303447 form the genetically matched control for the ioGlutamatergic Neurons TDP-43 M337V heterozygous disease model. This physiologically-relevant isogenic pairing offers a powerful next generation model to study amyotrophic lateral sclerosis ALS and frontotemporal dementia FTD in research and drug discovery. ioGlutamatergic Neurons TDP-43 M337V heterozygous are ioGlutamatergic Neurons carrying a genetically engineered M337V mutation in the TARDBP gene, encoding TAR DNA binding protein 43 TDP-43 . ioGlutamatergic Neurons TDP-43 M337V heterozygous have been reprogrammed from human iPSCs using opti-oxTM technology, a precise reprogramming technology. Human stem cells, within days, convert consistently into mature, functional glutamatergic neurons providing a high quality human model for the study of ALS and FTD. ioGlutamatergic Neurons TDP-43 M337V heterozygous express pan-neuronal and glutamatergic markers TUBB3, MAP2 and VGLUT2 by day 11. This disease model offers a fast and easy-to-use system for investigations into the impact of gene function on disease progression against an isogenic control. A homozygous disease model is also available ab307781 . In partnership with bit.bio Karyotype: Normal Seeding Density: 30,000 cells/cm2 Seeding compatibility: 6-, 12-, 24-, 96- and 384-well compatible Quality control: ICC and gene expression analysis Research applications: Academic research, Drug development, Neurotoxicology, Genetic screening e.g. CRISPR screening . This product is subject to limited use licenses from iPS Academia Japan Inc, TET Systems GmbH, ERS Genomics Limited and Sigma-Aldrich Co. LLC and is developed with Bit Bio patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.